Wysera-L Capsule SR is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Rabeprazole 20 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties, facilitating gastric motility and reducing symptoms such as nausea, vomiting, and dyspepsia. Rabeprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby promoting ulcer healing and providing symptomatic relief in acid-related conditions. This sustained-release capsule formulation ensures prolonged therapeutic action, enhancing patient compliance and efficacy. Wysera-L is indicated for the treatment of gastroesophageal reflux disease (GERD), functional dyspepsia, peptic ulcer disease, and other acid-peptic disorders where impaired gastric motility and acid hypersecretion coexist. The combination therapy addresses both motility dysfunction and acid suppression, offering comprehensive symptom control. Wysera-L should be administered under medical supervision, with dosage adjustments based on clinical response and patient tolerance. Caution is advised in patients with renal or hepatic impairment, and potential drug interactions should be considered. Adverse effects may include mild gastrointestinal disturbances, headache, or dizziness. Overall, Wysera-L Capsule SR provides an effective therapeutic option for complex gastrointestinal conditions requiring dual-action treatment.